Rimabotulinumtoxinb

Summary

Rimabotulinumtoxinb (CHEMBL1201569) is an approved protein; indicated across 9 conditions including atrial fibrillation and carpal tunnel syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 9 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201569
Name	Rimabotulinumtoxinb
Type	Protein
Max phase	4

Also known as: AN-0772, AN0772, Botulin b, Botulinum b toxin, Botulinum neurotoxin type b, Botulinum toxin type b, BTX-8, BTX-B, Myobloc, Neurobloc, Rimabotulinumtoxinb, RIMABOTULINUMTOXINB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
atrial fibrillation	2	MONDO:0004981	EFO:0000275
carpal tunnel syndrome	2	MONDO:0007275	EFO:0004143
dementia	2	MONDO:0001627	HP:0000726
cerebral palsy	1	MONDO:0006497	EFO:1000632

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	3
PHASE4	2
PHASE3	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00702754	PHASE4	COMPLETED	Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
NCT02052024	PHASE4	COMPLETED	Myobloc Atrophy Study
NCT01994109	PHASE3	COMPLETED	Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
NCT02610868	PHASE3	COMPLETED	Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
NCT00165776	PHASE2	COMPLETED	Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
NCT00238641	PHASE1/PHASE2	COMPLETED	DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?
NCT01930604	PHASE2	UNKNOWN	Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
NCT03007004	PHASE2	COMPLETED	Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis
NCT03103074	Not specified	COMPLETED	Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).